Welcome to our dedicated page for ASP Isotopes SEC filings (Ticker: ASPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ASP Isotopes's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ASP Isotopes's regulatory disclosures and financial reporting.
On 23 Jul 2025 ASP Isotopes Inc. (ASPI) executed an Underwriting Agreement with Cantor Fitzgerald covering a registered direct offering of 7,500,000 common shares at $8.00 each. The underwriters will acquire the shares at $7.52, reflecting customary underwriting fees.
ASPI projects net proceeds of ≈ $56.2 million after commissions and expenses. Closing is slated for 25 Jul 2025, subject to standard conditions, under the company’s effective Form S-3 shelf (File No. 333-286860) and a related Rule 462(b) registration statement.
Simultaneously, the company terminated its unused $25 million at-the-market Equity Distribution Agreement with Canaccord Genuity, opting instead for the fully underwritten raise. Exhibits include the underwriting agreement (1.1), Blank Rome LLP legal opinion (5.1), and a pricing press release (99.1).
ASP Isotopes (Nasdaq: ASPI) is raising $60 million through a firmly underwritten public offering of 7.5 million new shares at $8.00, a 20% discount to the $10.00 last close. After $3.6 million in underwriting fees and $0.2 million expenses, net proceeds will be ≈$56.2 million. Outstanding shares will rise 9% to 91.6 million, creating immediate dilution of $6.80 per share; adjusted tangible book value moves from $0.54 to $1.20.
Management plans to deploy cash for general corporate purposes and cap-ex as it transitions from commissioning to initial commercial production of C-14, Si-28 and Yb-176 in 2025. Pro-forma cash (3/31/25 balance $56 million + summer raises + this offering) extends the runway beyond 12 months.
Strategic catalysts include: 1) a $22 million TerraPower loan and two HALEU supply agreements valued up to $4.1 billion over 2027-37 (subject to licensing and plant completion); 2) the proposed all-stock acquisition of Renergen (max 14.27 million ASPI shares) to add helium/LNG assets; 3) a planned H2-25 spin-out of Quantum Leap Energy, its HALEU subsidiary. Each transaction faces regulatory, funding and execution risk.
The company remains pre-revenue, reporting <$8.4 million> Q1-25 net loss and <$32.3 million> FY-24 loss, and warns it may need additional capital. Shares have traded between $0.32 and $10.49 since IPO, highlighting volatility.
ASP Isotopes (ASPI) is raising $60 M gross ($56.4 M net) via a 7.5 M share follow-on priced at $8, a 20% discount to the $10.00 last sale. The new total share count will be about 91.6 M. Proceeds are earmarked for general corporate purposes and extend liquidity beyond 12 months; cash at 3/31/25 was $56 M and the company has since raised an additional $51.7 M.
The company is commercialising isotope-enrichment technologies (ASP & QE) and reports commissioning of three South African plants (C-14, Si-28, Yb-176) with first product expected in 2025. Major strategic actions include: 1) $22 M TerraPower loan plus two HALEU supply agreements valued up to $4.1 B through 2037; 2) planned spin-out of Quantum Leap Energy (HALEU & Li-6) in H2-25; and 3) an all-share acquisition of Renergen (up to 14.27 M ASPI shares) that would add helium/LNG assets, pending multiple regulatory approvals.
ASPI remains pre-revenue, logging net losses of $8.4 M in Q1-25 and $32.3 M in FY-24. The offer dilutes existing holders by an estimated $6.80 per share of tangible book value. Underwriters Cantor and Canaccord will deliver shares on or about 25 Jul 25; lock-ups run 90 days (company) and 75 days (insiders).
On July 11, 2025, ASP Isotopes Inc. (NASDAQ: ASPI) filed a Form 8-K (Item 8.01) to disclose that shareholders of Renergen Limited have approved the scheme of arrangement for ASP Isotopes’ proposed acquisition. The approval eliminates a major condition precedent and materially advances the transaction toward closing. A press release describing the vote is attached as Exhibit 99.1 (the fifth and sixth paragraphs are expressly excluded from incorporation by reference).
The filing contains no purchase price, financing structure, or anticipated closing timetable, and it includes no additional financial statements under Item 9.01 beyond the press-release exhibit. Accordingly, the report functions primarily as a regulatory notice highlighting a positive milestone in ASP Isotopes’ M&A strategy rather than providing quantitative information.